| |
AbCellera unlocks high-value drug classes, targets, and modalities, including T–cell engagers, antibody-drug conjugates, transmembrane proteins, and peptide-MHCs. Explore More. 
|
|
Today’s Big NewsJan 31, 2024 |
| By Nick Paul Taylor Novartis’ anti-TIM-3 antibody has flunked a phase 3 blood cancer trial, prompting the Swiss drugmaker to pull the drug candidate from its pipeline. The failed study was the biggest test to date of an immuno-oncology target into which a who’s who of leading drug developers have pumped money. |
|
|
|
By Max Bayer It's early days, but Novo Nordisk’s oral, long-acting, GLP-1 and amylin weight loss drug was found to be safe and effective in a phase 1 trial, spurring plans to widen the development plan, Martin Holst Lange, EVP and head of development, told investors Wednesday. |
By Nick Paul Taylor GSK is moving to ease worries about the looming loss of exclusivity on its HIV blockbuster, setting out plans to launch at least 12 major products and deliver more than 38 billion pounds ($48 billion) in risk-adjusted sales by 2031. |
By Annalee Armstrong Windtree Therapeutics is doing everything possible to advance a pipeline of cardiovascular meds, but it’s still not enough. The biotech is now hunting for a buyer of the entire operation rather than just a simple licensing deal. |
By Gabrielle Masson After a phase 2 flop late last year, allogeneic T-cell company Atara Biotherapeutics is laying off 25% of staff and sending its chief medical officer out the door. |
By Annalee Armstrong Allogene Therapeutics has dropped the bulk of a cell therapy collaboration with Notch Therapeutics, leaving just one chimeric antigen receptor (CAR) target from the original deal. |
By Annalee Armstrong Catamaran Bio’s voyage is ending early as the cell therapy biotech winds down operations and tries to find a new partner for its allogeneic solid tumor therapies. |
By Max Bayer Tectonic is jumping to Wall Street through a reverse merger with Avrobio. The latter biotech waved the white flag last summer to search for buyers. |
By Eric Sagonowsky Biogen is discontinuing its first Alzheimer's disease therapy, Aduhelm, after walking a rocky path. The company is taking a $60 million charge, halting sales and terminating a confirmatory trial. |
By Andrea Park In a giant leap for medtech-kind, a robotic surgery system is now en route to the International Space Station. |
Fierce podcasts Don’t miss an episode |
| While it’s a known fact that women, on average, live longer than men, a recent report unveils a nuanced reality—women also spend more of their lives grappling with poor health. This week on “The Top Line,” Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, explores the root causes behind this disparity and the multifacted nature of the women’s health gap. |
|
|---|
|
|
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle. 
|
|
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
